A number of firms have modified their ratings and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) recently:

  • 9/26/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $116.00 price target on the stock.
  • 9/21/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $113.00 price target on the stock.
  • 9/15/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at BMO Capital Markets.
  • 9/14/2017 – BioMarin Pharmaceutical is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $113.00 price target on the stock.
  • 9/14/2017 – BioMarin Pharmaceutical is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating and a $93.00 price target on the stock.
  • 8/31/2017 – BioMarin Pharmaceutical is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $98.00 price target on the stock.
  • 8/25/2017 – BioMarin Pharmaceutical was given a new $116.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 8/17/2017 – BioMarin Pharmaceutical was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/16/2017 – BioMarin Pharmaceutical is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $100.00 price target on the stock.
  • 8/9/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $119.00 price target on the stock, up previously from $118.00.
  • 8/7/2017 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $108.00 price target on the stock.
  • 8/4/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 8/4/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $107.00 price target on the stock.

BioMarin Pharmaceutical Inc. (BMRN) traded down 0.55% during trading on Tuesday, reaching $93.21. 929,442 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $88.49 and a 200 day moving average price of $89.61. BioMarin Pharmaceutical Inc. has a 1-year low of $78.42 and a 1-year high of $100.51. The stock’s market capitalization is $16.34 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The firm had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. During the same quarter in the prior year, the firm posted ($2.61) earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts expect that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current year.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $90.50, for a total value of $1,357,500.00. Following the sale, the insider now directly owns 141,422 shares in the company, valued at $12,798,691. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $91.26, for a total value of $342,225.00. Following the completion of the sale, the director now owns 19,660 shares in the company, valued at $1,794,171.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,686 shares of company stock worth $3,736,318. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related stocks with our FREE daily email newsletter.